

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial


Rebecca A. Dent¹, Zhimin Shao², Peter Schmid³, Javier Cortés⁴, David W. Cescon⁵, Shigehira Saji⁶, Kyung Hae Jung⁷, Thomas Bachelot⁸, Shouman Wang⁹, Gul Basaran¹⁰, Yee Soo Chae¹¹,

Rofhiwa Mathiba¹², Shin-Cheh Chen¹³, Agostina Stradella¹⁴, Nicola Battelli¹⁵,

Naoki Niikura¹⁶, Kechen Zhao¹⁷, Petra Vuković¹⁸,

Micah J. Maxwell¹⁹, Tiffany A. Traina²⁰

¹National Cancer Center Singapore, Singapore; ²Fudan University Shanghai Cancer Center, Fudan, China; ³Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK; ⁴International Breast Cancer Center (IBCC), Pangaea Oncology, Barcelona, Spain; ⁵Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁶Fukushima Medical University, Fukushima, Japan; ⁷Asan Medical Center – University of Ulsan College of Medicine, Seoul, Republic of Korea; 8Centre Léon Bérard, Lyon, France; 9Xiangya Hospital of Central South University, Changsha, China; 10 MAA Acibadem University, School of Medicine, Medical Oncology Department, Istanbul, Türkiye; 11 Kyungpook National University Chilgok Hospital, Kyungpook National University School of Medicine, Kyungpook, Republic of Korea; ¹²Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa; ¹³Chang Gung Medical Foundation – Taipei Chang Gung Memorial Hospital, Taipei City, Taiwan; 14 Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona, Spain; ¹⁵Ospedale Generale Provinciale Macerata, Macerata, Italy; ¹⁶Tokai University School of Medicine, Kanagawa, Japan; ¹⁷Biometrics, Late-Stage Development, Oncology R&D, Astra Zeneca, Wilmington, DE, USA; 18 Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK; 19 Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA; ²⁰Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA



Declaration of Interests

Rebecca A. Dent

- Consulting or Advisory Role:
 - AstraZeneca, MSD, Pfizer, Eisai, Novartis, Daiichi Sankyo/AstraZeneca, Roche, Gilead Sciences
- Travel, Accommodation, Expenses:
 - AstraZeneca, MSD, Pfizer, Eisai, Novartis, Daiichi Sankyo/AstraZeneca, Roche
- Honoraria:
 - AstraZeneca, MSD, Pfizer, Eisai, Novartis, Daiichi Sankyo/AstraZeneca, Roche, Gilead Sciences, DKSH
- Research Funding (to Institution):
 - Roche, AstraZeneca



Background

Advanced/metastatic TNBC is the most aggressive cancer subtype with the fewest treatment options Metastatic TNBC 5-year OS: 14.9%¹



~70% not candidates for 1L immunotherapy²

For these patients, there have been no new 1L drug approvals in over a decade; chemotherapy remains the mainstay of 1L care^{4,5} and is associated with poor patient outcomes^{6–8}



~50% do not receive treatment beyond 1L^{2,3}

Many patients do not receive 2L treatment, highlighting the critical unmet need for more effective 1L options

TROPION-Breast02 was designed to determine whether 1L Dato-DXd can improve clinical outcomes in patients with locally recurrent inoperable or metastatic TNBC for whom immunotherapy is not an option

1. National Cancer Institute SEER Program. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html; 2. Punie K, et al. Oncologist 2025;30:oyaf034; 3. Traina T, et al. Clin Cancer Res 2025;31:P3-08-10; 4. Trapani D, et al. Ann Oncol 2025; doi: 10.1016/j.annonc.2025.07.017; 5. Moy B, et al. J Clin Oncol 2021;39:3938–58; 6. Shi M, et al. Cancer Pathog Ther 2023;2:81–90; 7. Kuderer NM, et al. Nat Rev Clin Oncol 2022;19:681–97; 8. Li CH, et al. Breast Cancer Res 2019;21:143.




TROPION-Breast02: Study Design

Randomised, phase 3, open-label, global study (NCT05374512)

Key inclusion criteria:

- Patients with histologically or cytologically documented locally recurrent inoperable or metastatic TNBC*
- No prior chemotherapy or targeted systemic therapy in the locally recurrent inoperable or metastatic setting
- Immunotherapy not an option[†]
- ECOG PS 0 or 1
- No minimum DFI[‡]



Endpoints

Dual primary:

- OS
- PFS by BICR per RECIST v1.1

Secondary included:

- PFS (investigator-assessed)
- ORR, DoR
- Safety

Randomisation stratified by:

- Geographic region (US/Canada/Europe vs other geographic regions)
- PD-L1 status (high [CPS ≥10] vs low [CPS <10])§
- DFI history (de novo vs prior DFI 0–12 months vs prior DFI >12 months)¶
- Treatment continued until investigator-assessed RECIST v1.1 progressive disease, unacceptable toxicity, or another discontinuation criterion was met
- Following progression or discontinuation of study treatment, patients could receive subsequent therapies, including approved ADCs or chemotherapy, at the investigator's discretion

*According to ASCO/CAP criteria. †Including patients with PD-L1-low tumours, or patients with PD-L1-high tumours with (a) disease relapse after prior PD-(L)1 inhibitor therapy for early-stage breast cancer, (b) comorbidities precluding PD-(L)1 inhibitor therapy, or (c) no regulatory access to PD-(L)1 inhibitor therapy. ‡DFI defined as time between date of completion of treatment with curative intent and date of first documented local or distant disease recurrence. §Recruitment of patients with PD-L1-high tumours who would otherwise be eligible for pembrolizumab if regulatory access was available was capped at ~10% of randomised patients. ¶Recruitment of patients with DFI 0–12 months: paclitaxel 80 mg/m² IV, D1, 8, 15, Q3W, or nab-paclitaxel 100 mg/m² IV, D1, 8, 15, Q4W; if prior taxane and DFI 0–12 months: capecitabine 1000 or 1250 mg/m² orally twice daily, D1–14, Q3W (dose determined by standard institutional practice), or eribulin mesylate 1.4 mg/m² / eribulin 1.23 mg/m² IV, Day 1, 8, Q3W, or carboplatin AUC6 IV, D1, Q3W. ¶In the Dato-DXd vs ICC arm, 65% vs 72% of patients received any subsequent therapy in any treatment line; 14% vs 30% received a subsequent ADC (sacituzumab govitecan, sacituzumab tirumotecan, trastuzumab deruxtecan).


Rebecca A. Dent

ADC, antibody-drug conjugate; BICR, blinded independent central review; CPS, combined positive score; D, day; DFI, disease-free interval; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenously; ORR, objective response rate; PD-(L)1, programmed cell death (ligand) 1; PFS, progression-free survival; QXW, every X weeks.



TROPION-Breast02: Statistical Methods

Multiple testing procedure with alpha-exhaustive recycling strategy for dual primary endpoints



 Study considered positive if PFS and/or OS analysis were statistically significant

- Data cutoff for primary PFS and final OS analysis:
 August 25, 2025
 - 408 observed PFS events by BICR (63% maturity)
 - 349 observed OS events (54% maturity)
 - Median study follow-up: 27.5 months (range 13.3–38.7)
 - 45 patients (14%) in the Dato-DXd group and 8 patients (3%) in the ICC group remained on study treatment



Demographics and Baseline Characteristics

		Dato-DXd (n=323)	ICC (n=321)
Median age (range), years		56 (27–85)	57 (23–83)
Female, n (%)		323 (100)	319 (99)
Race, n (%)	Black or African American Asian White Other*	13 (4) 151 (47) 131 (41) 28 (9)	14 (4) 131 (41) 153 (48) 23 (7)
Geographic region, n (%)	US, Canada, Europe Other geographic regions	120 (37) 203 (63)	120 (37) 201 (63)
ECOG PS, n (%)	0 1	195 (60) 128 (40)	182 (57) 139 (43)
DFI history, n (%)	De novo Prior DFI 0–12 months [‡] Prior DFI 0–6 months Prior DFI >12 months [‡]	109 (34) 67 (21) 47 (15) 147 (46)	110 (34) 66 (21) 51 (16) 145 (45)


		Dato-DXd (n=323)	ICC (n=321)
PD-L1 status,† n (%)	Low (CPS <10)	287 (89)	291 (91)
	High (CPS ≥10)	34 (11)	29 (9)
Metastases, n (%)	Visceral	253 (78)	233 (73)
	Liver	93 (29)	98 (31)
	Brain [§]	36 (11)	28 (9)
Number of metastatic sites, n (%)	<3	207 (64)	215 (67)
	≥3	116 (36)	106 (33)
Pre-selected choice of chemotherapy, n (%)	Nab-paclitaxel Paclitaxel Eribulin mesylate/eribulin Carboplatin Capecitabine	180 (56) 82 (25) 43 (13) 11 (3) 7 (2)	172 (54) 92 (29) 35 (11) 14 (4) 8 (2)

^{*}Including not reported. †Based on central laboratory testing, using Agilent PD-L1 IHC 22C3 pharmDx Assay (Agilent Technologies, Santa Clara, CA); PD-L1 status missing/not applicable in 2 patients in the Dato-DXd arm and 1 patient in the ICC arm. ‡Prior (neo)adjuvant cancer therapy was received by 66% of patients, including nitrogen mustards (57%), taxanes (57%), anthracyclines (56%), pyrimidine analogues (27%), platinum compounds (16%), and PD-(L)1 inhibitors (5%). §Patients with asymptomatic, stable brain metastases were permitted in the study.






Progression-Free Survival by BICR



Dato-DXd demonstrated a statistically significant and clinically meaningful improvement in PFS compared with ICC, reducing the risk of progression or death by 43%




Progression-Free Survival by Investigator Assessment



PFS by investigator assessment was consistent with PFS by BICR




Overall Survival



Dato-DXd demonstrated a statistically significant and clinically meaningful improvement in OS compared with ICC, reducing the risk of death by 21%



PFS by BICR Subgroup Analysis




^{*}Patients with asymptomatic, stable brain metastases were permitted in the study.





OS Subgroup Analysis



[†]Ad hoc analysis of the US cohort showed comparable OS HR to the ITT population.

Rebecca A. Dent



Overall Safety Summary

Median total treatment duration:

— Dato-DXd: 8.5 months (range 0.7–38.0)

-ICC: 4.1 months (range 0.1–32.0)

Patients with total exposure >12 months:

- Dato-DXd: 35.1%

-ICC: 9.4%

Treatment-related AEs, n (%)	Dato-DXd (n=319)	ICC (n=309)
Any grade	296 (93)	257 (83)
Grade ≥3	105 (33)	89 (29)
Serious TRAEs	29 (9)	26 (8)
Associated with dose interruption	76 (24)	60 (19)
Associated with dose reduction	85 (27)	56 (18)
Associated with discontinuation	14 (4)	23 (7)
Associated with death	0	0

Despite more than double the median duration of treatment in the Dato-DXd arm, rates of grade ≥3 and serious treatment-related AEs were similar, and discontinuations were lower, with Dato-DXd vs ICC



Most Common Treatment-Related AEs (≥15% of Patients)

Treatment related AEc. p. (9/)	Dato-DX	d (n=319)	ICC (n=309)		
Treatment-related AEs, n (%)	Any Grade	Grade ≥3	Any Grade	Grade ≥3	
Dry eye*	76 (24)	4 (1)	9 (3)	0	
Stomatitis	182 (57)	27 (8)	27 (9)	0	
Nausea	142 (45)	2 (<1)	53 (17)	2 (<1)	
Constipation	72 (23)	1 (<1)	31 (10)	0	
Vomiting	65 (20)	4 (1)	23 (7)	1 (<1)	
Decreased appetite	49 (15)	1 (<1)	20 (6)	1 (<1)	
Neutropenia [†]	39 (12)	10 (3)	90 (29)	40 (13)	
Anaemia [‡]	48 (15)	6 (2)	64 (21)	10 (3)	
Leukopenia [§]	27 (8)	3 (<1)	55 (18)	13 (4)	
Peripheral neuropathy [¶]	14 (4)	0	75 (24)	5 (2)	
Alopecia	130 (41)	0	96 (31)	1 (<1)	
Fatigue#	101 (32)	8 (3)	86 (28)	9 (3)	

^{*}In the Dato-DXd arm only, ophthalmologic assessments were required every 3 cycles while on therapy; this was not required in the ICC arm. For all patients in both arms, ophthalmologic assessments were required at baseline, as clinically indicated, and at end of therapy.

†Grouped term comprising preferred terms of neutropenia and neutrophil count decreased. †Grouped term comprising preferred terms of haemoglobin decreased, anaemia, and haematocrit decreased. §Grouped term comprising preferred terms of white blood cell count decreased and leukopenia. ¶Grouped term comprising preferred terms of neuropathy peripheral, peripheral motor neuropathy, polyneuropathy, paraesthesia, and peripheral sensory neuropathy. #Grouped term comprising preferred terms of fatigue, asthenia, and malaise.

□Per Common Terminology Criteria for Adverse Events version 5.0, the maximum grade for alopecia is grade 2.

Rebecca A. Dent



Treatment-Related AESIs for Dato-DXd

AESI category, n (%)	Dato-DXd (n=319)		ICC (n=309)			
Preferred term*	Grade 1	Grade 2	Grade ≥3	Grade 1	Grade 2	Grade ≥3
Oral mucositis/stomatitis†	78 (24)	87 (27)	27 (8)	22 (7)	8 (3)	0
Stomatitis	72 (23)	83 (26)	27 (8)	19 (6)	8 (3)	0
Ocular surface events ^{‡§}	76 (24)	50 (16)	23 (7)	9 (3)	5 (2)	1 (<1)
Dry eye	51 (16)	21 (7)	4 (1)	6 (2)	3 (1)	0
Keratitis	21 (7)	14 (4)	7 (2)	1 (<1)	0	0
Conjunctivitis	7 (2)	13 (4)	1 (<1)	0	0	0
Adjudicated drug-related ILD/pneumonitis¶	1 (<1)	7 (2)	1 (<1)#	1 (<1)	1 (<1)	0

Treatment-related oral mucositis/stomatitis:

- In the Dato-DXd arm, events led to dose interruption, reduction, and discontinuation in 11 (3%), 36 (11%), and 0 patients, respectively
- Grade ≥2 events resolved to grade ≤1 in 103/114 patients (90%) at data cutoff

Treatment-related ocular surface events:


- In the Dato-DXd arm, events led to dose interruption, reduction, and discontinuation in 18 (6%), 14 (4%), and 3 (<1%) patients, respectively
- Grade ≥2 events resolved to grade ≤1 in 49/73 patients (67%) at data cutoff

*Details for preferred terms included if reported in ≥20 patients in either arm. †Comprising the preferred terms of aphthous ulcer, mouth ulceration, oral pain, oropharyngeal inflammation, and stomatitis. ‡Comprising the preferred terms of acquired corneal dystrophy, blepharitis, conjunctivitis, corneal disorder, corneal epithelium defect, corneal exfoliation, corneal exfoliation, corneal toxicity, dellen, dry eye, keratitis, keratopathy, lacrimation increased, limbal stem cell deficiency, meibomian gland dysfunction, photophobia, punctate keratitis, ulcerative keratitis, vision blurred, visual acuity reduced, visual impairment, and xerophthalmia. §In the Dato-DXd arm only, ophthalmologic assessments were required every 3 cycles while on therapy; this was not required in the ICC arm. For all patients in both arms, ophthalmologic assessments were required at baseline, as clinically indicated, and at end of therapy. ¶Comprising the preferred terms of interstitial lung disease and pneumonitis. #Grade 5 – this event was characterised by the investigator as grade 3 pneumonitis, with death assessed as related to breast cancer.





Response by BICR




	Dato-DXd (n=323)	ICC (n=321)			
Confirmed objective response, n (%)	202 (62.5)	94 (29.3)			
Odds ratio (95% CI)	4.24 (3.03–5.95)				
Best confirmed objective response, n (%)					
Complete response	29 (9.0)	8 (2.5)			
Partial response	173 (53.6)	86 (26.8)			
Stable disease	87 (26.9)	151 (47.0)			
Progressive disease	27 (8.4)	52 (16.2)			
Not evaluable	7 (2.2)	24 (7.5)			

With Dato-DXd, confirmed ORR was more than double that with ICC, and confirmed complete response rate was more than three times that with ICC




Duration of Response



With Dato-DXd, median duration of response was >1 year



ORR by BICR Subgroup Analysis



Rebecca A. Dent



Conclusions

- TROPION-Breast02 met both dual primary endpoints: first-line Dato-DXd demonstrated statistically significant and clinically meaningful improvement in **OS and PFS** over ICC
 - OS HR 0.79 (95% CI 0.64-0.98); P=0.0291
 - PFS by BICR HR 0.57 (95% CI 0.47–0.69); P<0.0001
 - ≥5-month improvement in both median OS and PFS

enrolled patients who are representative of the real-world TNBC population, including those often excluded from clinical trials (e.g. 15% had DFI 0–6 months)

- The Dato-DXd safety profile was manageable and generally consistent with the known profile
 - Despite more than double the median duration of treatment, rates of grade ≥3 and serious TRAEs were similar, and discontinuations were lower, with Dato-DXd vs ICC

TROPION-Breast02 results support Dato-DXd as the new first-line standard of care for patients with locally recurrent inoperable or metastatic TNBC for whom immunotherapy is not an option



Acknowledgements

The authors would like to particularly thank:

- Patients
- Families and caregivers
- TROPION-Breast02 investigators and site personnel

TROPION-Breast02 (NCT05374512) is sponsored by AstraZeneca. In July 2020, Daiichi-Sankyo entered into a global development and commercialisation collaboration with AstraZeneca for Dato-DXd.

Medical writing support for the development of this presentation, under the direction of the authors, was provided by Helen Kitchen and Ella Spencer of Ashfield MedComms (Macclesfield, UK), an Inizio Company, in accordance with Good Publications Practice guidelines (https://www.ismpp.org/gpp-2022), and was funded by AstraZeneca.



Disclaimer: Copies of this presentation obtained through Quick Response or text key codes are for personal use only and may not be reproduced without written permission of the authors.

Scan the QR code:

- To obtain a copy of these slides
- To access a plain language summary infographic





Thank you

European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org

esmo.org

